

CKS-17

Cat. No.:	HY-P3051
CAS No.:	99273-04-8
Molecular Formula:	C ₈₇ H ₁₄₈ N ₂₆ O ₂₄
Molecular Weight:	1942.27
Sequence Shortening:	LQNRRLDLLFLKEGGL
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	CKS-17 is a synthetic retroviral envelope peptide. CKS-17 has the highly conserved amino acid sequences occurring within the transmembrane envelope protein of many animal and human retroviruses. CKS-17 acts as an immunomodulatory epitope and exhibits suppressive properties for numerous immune functions ^{[1][2][3]} .								
In Vitro	CKS-17 (THP-1 cells) induces increased intracellular cAMP via activation of adenylate cyclase ^[1] . CKS-17 (15 μM; EL4 cells) inhibits interleukin-2 production by tumor cell products ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	CKS-17 (10 μM; i.d.; B6AF1 mice and C57BL/6J mice) inhibits delayed-type hypersensitivity (DTH) reactions to sheep erythrocytes in the feet of mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table> <tr> <td>Animal Model:</td> <td>B6AF1 mice and C57BL/6J mice with DTH models^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 μM</td> </tr> <tr> <td>Administration:</td> <td>Intradermal injection, into the right hind footpad</td> </tr> <tr> <td>Result:</td> <td>Had a transient depressive effect on DTH reaction.</td> </tr> </table>	Animal Model:	B6AF1 mice and C57BL/6J mice with DTH models ^[2]	Dosage:	10 μM	Administration:	Intradermal injection, into the right hind footpad	Result:	Had a transient depressive effect on DTH reaction.
Animal Model:	B6AF1 mice and C57BL/6J mice with DTH models ^[2]								
Dosage:	10 μM								
Administration:	Intradermal injection, into the right hind footpad								
Result:	Had a transient depressive effect on DTH reaction.								

REFERENCES

- [1]. Haraguchi S, et, al. Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5568-71.
- [2]. Nelson M, et, al. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother. 1989;30(2):113-8.
- [3]. Nelson M, et, al. Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother. 1990;30(6):331-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA